Page 6 - HIV/AIDS Guidelines
P. 6

Table of Contents

            What’s New in the Guidelines? ..............................................................................................................i

            Guidelines Panel Roster .......................................................................................................................vii

            Financial Disclosure..............................................................................................................................ix
            Introduction..........................................................................................................................................A-1
                   Table 1. Outline of the Guidelines Development Process...........................................................A-2

                   Table 2. Rating Scheme for Recommendations...........................................................................A-3
            Baseline Evaluation.............................................................................................................................B-1

            Laboratory Testing...............................................................................................................................C-1
                   Laboratory Testing for Initial Assessment and Monitoring
                   While on Antiretroviral Therapy.................................................................................................C-1
                       Table 3. Laboratory Monitoring Schedule for Patients Prior to and
                       After Initiation of Antiretroviral Therapy..............................................................................C-2
                   CD4 T-Cell Count .......................................................................................................................C-4
                   Plasma HIV RNA Testing ...........................................................................................................C-6
                   Drug-Resistance Testing..............................................................................................................C-8

                       Table 4. Recommendations for Using Drug-Resistance Assays..........................................C-12
                   HLA-B*5701 Screening............................................................................................................C-16
                   Coreceptor Tropism Assays.......................................................................................................C-18

            Treatment Goals...................................................................................................................................D-1
            Initiating Antiretroviral Therapy in Treatment-Naive Patients ...................................................E-1

            What to Start: Initial Combination Regimens for the Antiretroviral-Naive Patient.................F-1
                   Table 5a. Preferred and Alternative Antiretroviral Regimens
                   for Antiretroviral Therapy-Naive Patients...................................................................................F-3
                   Table 5b. Acceptable Antiretroviral Regimens for Treatment-Naive Patients.............................F-4

                   Table 6. Advantages and Disadvantages of Antiretroviral Components
                   Recommended as Initial Antiretroviral Therapy .......................................................................F-16
                   Table 7. Antiretroviral Components or Regimens Not Recommended as Initial Therapy.........F-20

            What Not to Use ...................................................................................................................................G-1
                   Table 8. Antiretroviral Regimens or Components That Should Not Be Offered At Any Time.....G-3

            Management of the Treatment-Experienced Patient.....................................................................H-1
                   Virologic and Immunologic Failure............................................................................................H-1
                   Regimen Simplification ............................................................................................................H-11

                   Exposure-Response Relationship and Therapeutic Drug Monitoring
                   (TDM) for Antiretroviral Agents...............................................................................................H-15

                       Table 9a. Trough Concentrations of Antiretroviral Drugs for Patients
                       Who Have Drug-Susceptible Virus .....................................................................................H-17


            Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents           iv

                            Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.
   1   2   3   4   5   6   7   8   9   10   11